Literature DB >> 16757605

Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Charles R Sims1, Victor L Paetznick, Jose R Rodriguez, Enuo Chen, Luis Ostrosky-Zeichner.   

Abstract

Agar-based antifungal susceptibility testing is an attractive alternative to the microdilution method. We examined the correlation between the microdilution, E-test, and disk diffusion methods for posaconazole against Candida spp. A total of 270 bloodstream isolates of Candida spp. with a broad range of posaconazole MICs were tested using the CLSI M27-A2 method for microdilution, as well as the M-44A method and E-test methods for agar-based testing on Mueller-Hinton agar supplemented with 2% glucose and 0.5 microg of methylene blue. MICs and inhibitory zone diameters at the prominent growth reduction endpoint were recorded at 24 and 48 h. The Candida isolates included Candida albicans (n = 124), C. parapsilosis (n = 44), C. tropicalis (n = 41), C. glabrata (n = 36), C. krusei (n = 20), C. lusitaniae (n = 3), and C. dubliniensis (n = 2). The overall concordance (i.e., the percentage of isolates within two dilutions) between the E-test and microdilution was 64.8% at 24 h and 82.6% at 48 h. When we considered an arbitrary breakpoint of < or = 1 microg/ml, the agreement between the E-test and microdilution methods was 87.8% at 24 h and 93.0% at 48 h. The correlation of MICs with disk diffusion zone diameters was better for the E-test than the microdilution method. Zone correlation for diameters produced by the disks of two manufacturers was high, with a Pearson test value of 0.941 at 24 h. The E-test and microdilution MICs show good concordance and interpretative agreement. The disk diffusion zone diameters are highly reproducible and correlate well with both the E-test and the microdilution method, making agar-based methods a viable alternative to microdilution for posaconazole susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757605      PMCID: PMC1489413          DOI: 10.1128/JCM.02591-05

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

5.  In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units.

Authors:  T G Gleason; A K May; D Caparelli; B M Farr; R G Sawyer
Journal:  Arch Surg       Date:  1997-11

Review 7.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

8.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

View more
  10 in total

1.  Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Authors:  Shawn A Messer; Daniel J Diekema; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

2.  Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Authors:  Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-02-14       Impact factor: 5.948

3.  Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.

Authors:  Barbara D Alexander; Terry C Byrne; Kelly L Smith; Kimberly E Hanson; Kevin J Anstrom; John R Perfect; L Barth Reller
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

Review 4.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

5.  Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.

Authors:  Jess F Peterson; Michael A Pfaller; Daniel J Diekema; Michael G Rinaldi; Katherine M Riebe; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

6.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

8.  Correlation between Etest, disk diffusion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization.

Authors:  Melyssa Negri; Mariana Henriques; Terezinha I E Svidzinski; Claudete Rodrigues Paula; Rosário Oliveira
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

10.  Synthesis, spectroscopic, and antimicrobial studies on bivalent zinc and mercury complexes of 2-formylpyridine thiosemicarbazone.

Authors:  Sulekh Chandra; Shikha Parmar; Yatendra Kumar
Journal:  Bioinorg Chem Appl       Date:  2009-04-29       Impact factor: 7.778

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.